17.36 +0.03 (0.17%)
After hours: 4:54PM EDT
|Bid||17.40 x 800|
|Ask||17.60 x 900|
|Day's range||16.90 - 17.83|
|52-week range||7.41 - 28.75|
|Beta (5Y monthly)||2.41|
|PE ratio (TTM)||N/A|
|Earnings date||05 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.50|
The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime.
SAN FRANCISCO , May 7, 2020 /CNW/ -- Invitae (NVTA), a leader in medical genetics, today announced the expansion of online ordering for its high-quality medical genetic tests to Canada . Through the service, Canadians can access genetic testing recommended in early pregnancy as well as cancer risk assessments using telehealth guidance and kits that can be shipped to and from home. The service provides easier access to the same high-quality, medical genetic testing that experts use and trust worldwide during a time when healthcare visits are being delayed and wait times to see clinicians are growing.
Ladies and gentlemen, thank you for standing by and welcome to the Invitae's First Quarter 2020 Financial Results Conference Call. Joining us today are Sean George, our CEO; Shelly Guyer, our CFO; Lee Bandekgey, our COO; Bob Nussbaum, our Chief Commercial Officer (sic); and Katherine Stueland, our Chief Commercial Officer.
The medical genetics company achieved record-high testing volume growth in Q1. But the COVID-19 outbreak began taking a toll late in the quarter.
Invitae (NVTA) delivered earnings and revenue surprises of 4.76% and 3.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of genetic-testing company Invitae (NYSE: NVTA) rose over 13% today on an upbeat day for the stock market. The S&P 500 rose over 1.5% as investors cheered plans by some countries and U.S. states to soon begin reopening parts of their economies. While the broad economic damage caused by the coronavirus pandemic might take quarters or years to repair, the genetic testing industry might experience a faster recovery.
Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases (“Detect”) program to facilitate faster diagnoses for children with lysosomal storage disorders (“LSDs”), including GM1 gangliosidosis and GM2 gangliosidosis, also known as Tay-Sachs/Sandhoff disease. LSDs are progressive, multi-system, inherited metabolic diseases associated with premature death, and genetic testing is a crucial first step to arriving at a diagnosis.
SAN FRANCISCO (AP) _ Invitae Corp. (NVTA) on Wednesday reported a loss of $76.9 million in its fourth quarter. The San Francisco-based company said it had a loss of 79 cents per share. The results missed Wall Street expectations.
Invitae (NVTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?